all

The National Lipid Association (NLA) has released a comprehensive clinical review titled “Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association.” This new guidance provides an in-depth examination of the diagnosis, management, and treatment landscape for familial chylomicronemia syndrome (FCS) — a rare and severe genetic disorder characterized by extremely high triglyceride levels (≥ 1,000 mg/dL) and an elevated risk of life-threatening recurrent acute pancreatitis.

The risk of atherosclerotic cardiovascular disease increases with advancing age. Elevated LDL-cholesterol and non-HDL-cholesterol levels remain predictive of incident atherosclerotic cardiovascular events among individuals older than 75 years. Risk prediction among older individuals is less certain because most current risk calculators lack specificity in those older than 75 years and do not adjust for co-morbidities, functional status, frailty, and cognition which significantly impact prognosis in this age group.

The digital tool entitled "NAFCS Digital PDF scoring tool" is attached for your use.  The digital calculator is based on the article published in the Journal of Clinical Lipidology. Hegele et al. wrote the publication utilizing the RAND/UCLA modified Delphi process. The NAFCS manuscript may potentially help distinguish FCS from MCS, another genetic form of severe hypertriglyceridemia. Additionally, it may be used to help confer a clinical diagnosis of FCS in the event of an indeterminate genetic test, or to identify appropriate candidates for genetic testing.¹